Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.
Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer_ [360p]
